Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comorbidity in limited disease small-cell lung cancer: Age-adjusted Charlson comorbidity index and its association with overall survival following chemoradiotherapy.
Fink CA, Weykamp F, Adeberg S, Bozorgmehr F, Christopoulos P, Lang K, König L, Hörner-Rieber J, Thomas M, Steins M, El-Shafie RA, Rieken S, Bernhardt D, Debus J. Fink CA, et al. Among authors: christopoulos p. Clin Transl Radiat Oncol. 2023 Jul 24;42:100665. doi: 10.1016/j.ctro.2023.100665. eCollection 2023 Sep. Clin Transl Radiat Oncol. 2023. PMID: 37564923 Free PMC article.
AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients.
Schneider MA, Christopoulos P, Muley T, Warth A, Klingmueller U, Thomas M, Herth FJ, Dienemann H, Mueller NS, Theis F, Meister M. Schneider MA, et al. Among authors: christopoulos p. Int J Oncol. 2017 Feb;50(2):365-372. doi: 10.3892/ijo.2017.3834. Epub 2017 Jan 2. Int J Oncol. 2017. PMID: 28101582 Free PMC article.
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.
Christopoulos P, Endris V, Bozorgmehr F, Elsayed M, Kirchner M, Ristau J, Buchhalter I, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Warth A, Bischoff H, Schirmacher P, Stenzinger A, Thomas M. Christopoulos P, et al. Int J Cancer. 2018 Jun 15;142(12):2589-2598. doi: 10.1002/ijc.31275. Epub 2018 Jan 24. Int J Cancer. 2018. PMID: 29363116 Free article.
Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma.
Christopoulos P, Kirchner M, Bozorgmehr F, Endris V, Elsayed M, Budczies J, Ristau J, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Lasitschka F, Bischoff H, Sotillo R, Schirmacher P, Thomas M, Stenzinger A. Christopoulos P, et al. Int J Cancer. 2019 Jan 1;144(1):190-199. doi: 10.1002/ijc.31893. Epub 2018 Oct 30. Int J Cancer. 2019. PMID: 30255938 Free article.
Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.
Allgäuer M, Budczies J, Christopoulos P, Endris V, Lier A, Rempel E, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Fröhling S, Penzel R, Thomas M, Schirmacher P, Stenzinger A. Allgäuer M, et al. Among authors: christopoulos p. Transl Lung Cancer Res. 2018 Dec;7(6):703-715. doi: 10.21037/tlcr.2018.08.14. Transl Lung Cancer Res. 2018. PMID: 30505715 Free PMC article. Review.
Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy.
Bernhardt D, Aufderstrasse S, König L, Adeberg S, Bozorgmehr F, Christopoulos P, Shafie RAE, Hörner-Rieber J, Kappes J, Thomas M, Herth F, Steins M, Debus J, Rieken S. Bernhardt D, et al. Among authors: christopoulos p. Cancer Manag Res. 2018 Nov 30;10:6563-6569. doi: 10.2147/CMAR.S180990. eCollection 2018. Cancer Manag Res. 2018. PMID: 30555261 Free PMC article.
294 results